Elpiscience (Suzhou) Biopharma, Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2018-03-20
- Employees
- -
- Market Cap
- -
- Website
- https://cn.elpiscience.com
Clinical Trials
3
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06623136
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳The First Affiliated Hospital of He'nan University of Science and Technology, Luoyang, China
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Phase 1
Active, not recruiting
- Conditions
- Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-06-23
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05717348
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
A Study of ES104 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05167448
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
News
No news found